A thorough understanding of the cognitive effects of antidepressant medications is essential given their frequency of use. This meta-analysis was conducted to investigate whether antidepressants differentially affect the various domains of cognitive functioning for depressed and non-depressed participants. An electronic search of PsycInfo, Medline and Google Scholar was conducted for all journal articles published between January 1998 and January 2017. Thirty-three studies were included enabling calculation of Hedges' g using a random effects model for the cognitive domains of divided attention, executive function, expressive language, immediate memory, perceptual motor skills, processing speed, recent memory, sustained attention, visuospatial-constructional skills and working memory. Results revealed that overall, antidepressants have a modest, positive effect on divided attention, executive function, immediate memory, processing speed, recent memory and sustained attention for depressed participants. Selective serotonin reuptake inhibitors (SSRI's) were found to have the greatest positive effect on cognition for depressed participants, as compared to the other classes of antidepressants analysed. Antidepressants did not significantly affect cognitive function in non-depressed participants.
Antidepressants are the most commonly prescribed class of psychotropic drugs in Australia (AIHW 2016) . Almost 2 million prescriptions were written for Sertraline alone in the 2015-16 financial year, at a total cost to the Australian Government of almost $15.5 million (PBS 2016) . There were 1.7 million people (7.8% of the Australian population) who had at least one Pharmaceutical Benefits Scheme (PBS) subsidised prescription for antidepressant medications filled in 2011 (ABS 2016) . This figure is greater in the United States, where between 1996 and 2005, the overall annual rate of antidepressant treatment increased from 5.84% to 10.12% (Olfson and Marcus 2009) . While undoubtedly the increasing awareness and de-stigmatisation of depression has contributed to the rise in prescribing rates of antidepressants over the past several decades, the drugs are now also prescribed for a number of conditions other than depression including anxiety, eating disorders, pain syndromes, sleep disorders and nicotine addiction (Ashare and McKee 2012; Elias et al. 2006) . Antidepressants are also prescribed 'off-label' for conditions such as fibromyalgia, migraine, attention-deficit-hyperactivity disorder, and digestive system disorders (Patten et al. 2007) .
Given the prevalence of antidepressant use, a thorough understanding of the cognitive consequences of these medications is essential (Stein and Strickland 1998) . This is especially important in the context of neuropsychological assessment, where performance on cognitive testing is often used to inform diagnostic formulations regarding the presence or absence of neurodegenerative conditions or brain injuries or to form opinions provided in medico-legal contexts (Crowe 2010) . Although several investigators have studied the effects of antidepressant use on cognition, many of these studies are limited by small sample sizes or the use of non-standardised measures to assess cognition. Furthermore, significant methodological heterogeneity exists in the literature with regard to study design, length of antidepressant use and sample population. This heterogeneity means clinicians lack a clear, succinct evidence-base to predict the way in which their client's antidepressant medication regimen could be expected to impact upon their performance during neuropsychological assessment.
Antidepressant Classes and Mechanism of Action
While debate persists in the literature with regard to the efficacy of antidepressants in the treatment of Major Depressive Disorder (MDD: Bech et al. 2000; Kirsch et al. 2008; Moncrieff et al. 2004; Nassir Ghaemi 2008) , it is generally accepted that the different classes of antidepressants are equally efficacious (Anderson 2000; MacGillivray et al. 2003; Williams et al. 2000) . However, the pharmacological action of each drug class differs, resulting in different side effect profiles. As such, prescribing is generally based on tolerability for the individual patient (Penn and Tracy 2012) .
Monoamine oxidase (MAO) inhibitors are the oldest class of antidepressants and include Phenelzine (e.g., Nardil), Tranylcypromine (e.g., Parnate) and Selegiline (e.g., Emsam). MAO's catalyse the oxidative deamination of a range of neurotransmitters including serotonin (5-HT), histamine, dopamine (DA), noradrenaline (NE) and adrenaline (AD: Shih et al. 1999; Tipton et al. 2004 ). The use of MAO's has been limited by their toxicity in overdose (Penn and Tracy 2012) and several drug-drug and drug-food adverse interactions (Livingston and Livingston 1996) . Currently MAO's are considered the drug of second or third resort, and are occasionally used in treatment resistant depression (Livingston and Livingston 1996) .
Tricyclic antidepressants (TCAs) include drugs such as Amitriptyline (e.g., Elavil), Clomipramine (e.g., Anafranil) and Imipramine (e.g., Tofranil). They produce a range of biochemical effects, with the key therapeutic action due to 5HT and NE reuptake inhibition (Yıldız et al. 2002) . In addition to antidepressant activity, TCA's produce some undesirable side effects including sedation and anticholinergic effects (Horst and Preskorn 1998) .
The introduction of the selective serotonin reuptake inhibitors (SSRIs) proved to be a major advancement in the pharmacotherapy of MDD, particularly with regard to limiting the unwanted side effects of the older drugs (Horst and Preskorn 1998 ). SSRI's exhibit a more specific neuropharmacological profile, and the only known action of these drugs is to inhibit the uptake of 5-HT. SSRI's are the first line treatment choice (O'Leary et al. 2015) and include Fluoxetine (e.g., Prozac), Sertraline (e.g., Zoloft) and Escitalopram (e.g., Lexapro) .
Specific serotonin and norepinephrine reuptake inhibitors (SNRI's), a relatively recent class of antidepressants, are a second line treatment choice and are characterised by a mixed action on both NE and 5-HT (Lambert and Bourin 2002) . Venlafaxine (e.g., Effexor), Desvenlafaxine (e.g., Pristiq) and Duloxetine (e.g., Cymbalta) are included in this class. Like the SSRI's, SNRI's do not act on the adrenergic, muscarinic, or histaminic receptors that are responsible for the majority of the adverse side effects associated with TCAs.
The pharmacological specificity of the newer generation antidepressants means they are generally considered to have a more favourable safety and tolerability profile than the TCA's and MAO's in both acute and long-term treatment of MDD Peretti et al. 2000) . Together, the SSRIs and SNRIs account for more than 90% of the global antidepressant market (Artigas 2013) .
A final group of 'atypical' antidepressants include Bupropion (e.g., Wellbutrin), Nefazodone (e.g., Serzone), and Mirtazapine (e.g., Avanza) as well as serotoninmodulator and stimulator's (SMS) such as Brintellix (e.g., Vortioxetine), are known to have multiple sites of antidepressant action but generally do not interact at sites associated with side effects or tolerance (Horst and Preskorn 1998 ). These drugs demonstrate a similar level of efficacy to the SSRI's and TCA's, however, have a more selective mechanism of action, thereby limiting adverse side effects (Connolly and Thase 2012) . Given that up to 50% of patients fail to achieve remission with first line antidepressant treatment (Fava 2003) , this group of drugs present a useful alternative to the SSRIs (Horst and Preskorn 1998) .
Depression, Cognition and Antidepressants
Cognitive symptoms are often experienced by individuals with MDD, and can be an important mediator of psychosocial impairment (Buist-Bouwman et al. 2008; McIntyre et al. 2013) . Deficits in memory (Airaksinen et al. 2004; Austin et al. 2001) , attention (Paelecke-Habermann et al. 2005; Porter et al. 2003) , executive function (Austin et al. 2001; McDermott and Ebmeier 2009; Paelecke-Habermann et al. 2005 ) and processing speed (McDermott and Ebmeier 2009; Nebes et al. 2000; Sheline et al. 2006 ) have been reported in depressed patients when compared to healthy controls. For depressed persons, performance on cognitive testing may be observed to improve following antidepressant treatment because of the amelioration of depressive symptoms, resulting in less fatigue, improved mood and increased motivation in the test situation (Shelton 2000) . When considering the impact that antidepressant medication may have on cognitive functioning, it is important to differentiate the effects of antidepressants on cognitive functioning mediated by a range of biological mechanisms, such as neurotransmitter changes or structural or functional brain changes (Andrade and Rao 2010) , from the effects secondary to mood improvement (Danion 1993) .
Few, and mostly small, clinical studies have been undertaken to assess the efficacy of antidepressants in MDD that specifically investigated cognition as a primary outcome measure (Biringer et al. 2009; Pehrson et al. 2015) . Another challenge posed by the existing literature is the wide variety of measures used to assess cognition (Keefe et al. 2014; McIntyre et al. 2013) , some of which have limited or even unknown psychometric properties. Furthermore, there is considerable inconsistency with regard to the domain of cognitive function these instruments have been stated to measure. As noted by Harrison et al. (2016) the use of standardised, reliable measures of cognition is essential in determining possible treatment effects. This methodological heterogeneity makes the comparison of results across studies challenging (Biringer et al. 2009 ).
Notwithstanding the aforementioned difficulties, there is some evidence to suggest that chronic use of some antidepressant medications may impair cognitive function (McClintock et al. 2010) . Given the anticholinergic and antihistaminergic properties of the TCA's for example, it is not surprising that they are generally considered to pose the greatest risk of cognitive impairment (Amado-Boccara et al. 1995; Brooks and Hoblyn 2007) . There is limited evidence with regard to the cognitive effects of MAO's, however this class of antidepressants appears to be neither deleterious nor enhancing (Brooks and Hoblyn 2007 ). SSRI's are generally considered to be safe with regard to cognitive functioning (Boggio et al. 2005) , however reports do exist of detrimental effects (Deakin et al. 2004; Paterniti et al. 1999; Wadsworth et al. 2005) . Conversely, some researchers have suggested that some antidepressants including SSRIs, SNRIs, dopamine modulators (e.g., bupropion), and norepinephrine inhibitors (e.g., reboxetine) may actually improve cognitive functioning (Brooks and Hoblyn 2007; Fann et al. 2001 ).
An early review by Amado-Boccara et al. (1995) highlighted several methodological concerns with the research on antidepressants and cognition, including a lack of standardised cognitive testing and heterogeneity with regard to participant selection, drug dose and treatment duration. With these caveats in mind, Amado-Boccara et al. (1995) concluded that when impairment in cognitive function was observed, it was primarily associated with antidepressants with strong anticholinergic or sedative effects. In more chronic users, depressed persons' cognitive function was observed to normalise in parallel with mood. More recently, Baune and Renger (2014) conducted a systematic review of the literature and concluded that the SSRI's, the SSRE Tianeptine, the SNRI's Duloxetine and Vortioxetine and other antidepressants such as Bupropion and Moclobemide, were associated with improvements in cognitive function in depression in the domains of learning, memory and executive function. Keefe et al. (2014) also conducted a systematic review on the cognitive effects of antidepressant monotherapy and augmentation pharmacotherapy on cognitive function in individuals with MDD. Their review included patients with mild to severe depression in addition to various comorbidities including heart failure, alcohol dependence, stroke, or 'other' conditions. In the monotherapy studies, several classes of antidepressants were included such as SSRI's, SNRI's and TCA's, as well as Apomorphine. A range of psychotropic medications were included in the augmentation studies including the aforementioned antidepressants in addition to Lithium, Estrogen, Tianeptine, Aripiprazole, Amisulpride, Fludrocortisone, Spironolactone and Ketamine, as well as drugs considered to be cognition-enhancing such as Galantamine and Donepezil. Several methodologies were examined in the review including placebo-controlled, active comparator and open-label studies. Although the authors calculated the effect size for each of the studies they reviewed, they did not meta-analytically quantify pooled effect sizes (Rosenblat et al. 2015) . Keefe et al. (2014) concluded that of the studies they reviewed, a statistically significant improvement in cognition with pharmacotherapy (when compared to placebo or untreated healthy controls) was found to occur in approximately 12% of the analysed cognitive assessments. When the effect sizes for each cognitive domain were combined across studies, only verbal memory was found to improve with monotherapy versus placebo. Rosenblat et al. (2015) conducted a meta-analysis with a more narrow focus. Their review included only randomised controlled trials (RCT's) and participants with MDD. They identified nine RCT's (2,550 participants) which investigated the cognitive effects of SMS antidepressants (e.g., Vortioxetine), SNRI's (e.g., Duloxetine), SSRI's (e.g., Paroxetine, Citalopram and Sertraline), MAO's (e.g., Phenelzine) or TCA's (e.g., Nortryptiline). For placebo controlled trials, they were able to pool effect sizes in the cognitive domains of psychomotor speed, cognitive control, executive function and delayed recall. Antidepressants were found to have a positive effect on psychomotor speed and delayed recall. No significant effects were found for the other cognitive domains. The authors commented that a high level of heterogeneity with regard to the cognitive assessments used in the identified clinical trials greatly limited their ability to pool data across several cognitive domains. They also identified a moderate level of heterogeneity when pooling standard mean difference (SMD) effect sizes, suggested to be due to the comparison of a range of different antidepressants, the inclusion of studies with different durations of treatment and different age groups.
Understandably, much of the research on antidepressants and cognition has focused on depressed persons, limiting the comparability of the effect of antidepressants in this population to other groups. This has also resulted in difficulty disentangling how antidepressants may affect cognition through biologically mediated mechanisms, such as neurotransmitter changes for example, from potential secondary effects, such as via mood improvement and reduced fatigue. Some work has been undertaken with populations who are not depressed, but may be prescribed antidepressants for other reasons, such as following a traumatic brain injury (Fann et al. 2001; Horsfield et al. 2002) , substance addiction (Kalechstein et al. 2013) , fibromyalgia (Mohs et al. 2012) , stroke (Jorge et al. 2010) , post-traumatic stress disorder (Jorge et al. 2010) or obsessive compulsive disorder (Nielen and Den Boer 2003) , with mixed findings. Still less research has been carried out on the cognitive effects of antidepressants in healthy individuals, mostly with ambiguous results (Repantis et al. 2009; Schmitt et al. 2002) . Repantis et al. (2009) conducted a systematic review and meta-analysis investigating the potential for antidepressants to promote neuroenhancement in healthy individuals and, although they commented that the studies reviewed were not specifically designed to examine neuroenhancement effects, they concluded that the existing literature did not provide consistent evidence for either an enhancing or adverse effect of antidepressants on cognition in healthy people.
The Current Study
Despite the difficulties inherent in conducting a meta-analysis on the effects of antidepressants on cognition, it remains important to provide a synthesis of the current evidence to better enable clinicians to make informed decisions regarding the possible impact of these drugs on cognitive functioning. An understanding of the way in which antidepressants affect cognition in different groups of people would be both clinically and theoretically useful, and may help to clarify the mechanisms by which antidepressants may impact cognition in depressed persons. The two recent reviews by Amado-Boccara et al. (1995) and Rosenblat et al. (2015) only included studies that investigated the cognitive effects of antidepressants in depressed samples. Of these, only Rosenblat et al. (2015) used standard meta-analytic procedures to quantitatively combine results. Rosenblat et al.'s findings were limited to an analysis of RCT's, and the authors were only able to obtain pooled effect sizes for four domains of cognitive functioning. While the data generated from RCT's is often regarded as one of the strongest levels of evidence, many researchers agree that nonrandomised studies (e.g. non-randomised trials, controlled before and after designs etc.), are also important sources of evidence and should be an integral part of assessing health care interventions (for a review see Peinemann et al. 2013 ). While it is acknowledged that methodological heterogeneity certainly exists in the literature, the systematic exploration of this heterogeneity presents opportunities to increase the relevance of conclusions drawn from included studies, and to enhance understanding of the evidence as a whole (Lau et al. 1998 ). As such, in order to examine a wide evidence base, the current meta-analysis will include appropriate studies of various methodologies. The primary objective of this meta-analysis was to extend on Rosenblat et al.'s (2015) study by assessing the effect of antidepressants on cognition through the examination of a range of participant groups. The analysis thus compares and contrasts the effects of the various antidepressant classes on cognition in depressed and non-depressed persons.
Method

Inclusion Criteria
Studies were included that examined the effect of antidepressants on cognitive function in adults over 18 years of age. Antidepressant medications, with the primary mechanism of action being monoamine modulation, from one or more of the following categories were included -selective serotonin reuptake inhibitors (SSRIs), selective serotonin and norepinephrine reuptake inhibitors (SNRIs), norepinephrine and dopamine reuptake inhibitors (NDRIs), serotonin antagonist and reuptake inhibitors, noradrenergic and specific serotonergic antidepressants, tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and serotonin-modulator and stimulators (SMS). We included studies that examined depressed persons, individuals with other illnesses (e.g., anxiety, traumatic brain injury etc.) and healthy controls.
Because the aim of the current review was to examine the impact of antidepressants on specific domains of cognitive functioning, only studies that reported results for one or more cognitive domain were included. Studies reporting only a single global cognitive score or screening measure (e.g. MMSE score) were excluded. Only those studies which employed objective, standardised measures of cognitive function that are widely used and referred to in either Lezak et al. (2012) or Strauss et al. (2006) were included. To ensure comparability of cognitive test scores between studies, papers were excluded if they used modified or adapted versions of standardised tests (including computerised versions when such modification was not part of the standardised administration of the test), or if insufficient detail was provided pertaining to method of test administration.
A range of study methodologies were included. This was in part due to the lack of randomised clinical trials in the literature, but also to ensure that a breadth of information was available for interrogation and possible inclusion in the meta-analysis (Harvey and Taylor 2010) . As noted by Shrier et al. (2007) , including a variety of study methodologies (both observational and randomized) in a meta-analysis is advantageous in many situations, and is becoming more commonplace particularly with regard to intervention studies (Cameron et al. 2015; Faber et al. 2016) . The inclusion of a range of methodologies also allows for investigation of potential moderator variables when examining heterogeneous findings in the literature, and sensitivity analyses were conducted to investigate potentially disparate findings dependent on study design. As such, randomised controlled trials, controlled before and after trials, and uncontrolled pre-post (parallel groups) studies were eligible for inclusion.
Search Strategy
An electronic search was conducted for all journal articles published between January 1998 and January 2017 (last date of search was the 17th of February 2017) that reported findings from a study or studies which investigated the effect of antidepressant drugs on cognitive function. Studies prior to 1998 were excluded given that Stein and Strickland (1998) published a review of the neuropsychological effects of prescription medications, including antidepressants, which covered the state of the literature up to that time.
PsycInfo, Medline and Google Scholar were searched using the following search terms -antidepressant, tricyclic, tetracyclic, TCA, monoamine oxidase inhibitor, MAOI, serotonin selective reuptake inhibitor, SSRI, dual serotonin and norepinephrine reuptake inhibitor, SNRI, serotonin-2 antagonist and reuptake inhibitor, SARI, noradrenaline and dopamine reuptake inhibitor, NDRI, noradrenergic and specific serotonergic antagonist, NaSSA, noradrenaline specific reuptake inhibitor, NRI, serotonin reuptake enhancer, imipramine, protriptyline, amitriptyline, doxepin, trimipramine, nortriptyline, desipramine, maprotiline, amoxepine, clomipramine, tranylcypromine, phenelzine, moclobemide, fluoxetine, fluvoxamine, sertraline, paroxetine, escitalopram, venlafaxine, duloxetine, nefazodone, trazodone, bupropion, mirtazapine, reboxetine and tianeptine combined with cogniti*, neuropsych*, psychomotor, learning, memory, language, executive function, attention and social cognition. The asterisk (i.e., the truncation symbol) allowed for the inclusion of alternate word endings of the search term (e.g., cogniti* yielded articles containing cognition or cognitive). Searches were limited to human studies and English language. The reference lists of previously conducted systematic reviews and meta-analyses examining antidepressants and cognitive function were also searched for relevant studies, as were the reference lists of studies identified from the initial electronic search.
Data Extraction and Statistical Analysis
Titles and abstracts of each of the articles identified in the search process were screened based on the inclusionexclusion criteria outlined above. Full-text articles that passed the screening process were assessed by two reviewers (CP and SW) for eligibility for inclusion in quantitative analyses. Where there was disagreement on inclusion, consensus was reached through discussion or via consultation with the senior researcher (SC). Data, as outlined below, were extracted using a standardised form. One review author (CP) extracted data from included studies, and a second author (SW) independently reviewed and checked the extracted data. Disagreements were resolved by discussion between the two reviewing authors. If no agreement could be reached, it was planned the third author would decide.
The following data were extracted from each included study using a standardised form -publication details (including authors, title, year, journal name), study characteristics (study design, number of participants), participant characteristics (health status of participants and control group, mean age), drug characteristics (drug type and class, dose, length of use), outcome measures (cognitive tests used, cognitive domain assessed) and cognitive test results required for calculation of effect size (usually means and standard deviations).
The primary outcome measure was the standardised mean difference (SMD), calculated as Hedges' g, for each relevant cognitive test score (Higgins and Green 2011; Sriganesh et al. 2016) . Hedges' g is a modification of Cohen's d that accounts for sample size bias, and can be calculated from studies that use two independent groups, paired groups or matched designs (Borenstein et al. 2009 ). It is interpreted using Cohen's guidelines, namely, 0.2 (small effect), 0.5 (medium effect) and 0.8 (large effect : Cohen 1988) . Depending on study design, the effect size indicated the difference between antidepressant users and controls, or the difference between pre-treatment and post-treatment scores. When participants were assessed at several time points, the longest time point from baseline (i.e. end point) was used in the analysis. For randomised controlled trials, an effect size was calculated using final cognitive scores for treated compared to placebo (Higgins and Green 2011) . When large pre-treatment differences in cognitive scores were identified, or if the treatment and control groups were not comparable (e.g. treatment group with MDD compared to a healthy control group), an effect size was calculated based on change from baseline. For controlled before and after studies, uncontrolled pre-post studies and cross over designs where participants acted as their own controls, the effect size was calculated as change from baseline.
None of the included studies reported data on the variance of pre-and post-test data. As recommended by the Cochrane Handbook for Systematic Review of Interventions and others (Follmann et al. 1992) , imputed correlation coefficients of 0.50 were used to impute the change-from-baseline standard deviation required to calculate an effect size. Sensitivity analyses revealed that the imputation of marginally lower (e.g., 0.2) or higher (e.g., 0.8) values did not significantly alter the effect size or confidence intervals for these outcomes. If mean or standard deviation values were not reported, these were calculated based on reported confidence intervals (CI) or pvalues. If standard error was reported, this was converted to standard deviation. Where insufficient data was provided in the article to calculate an effect size, the authors were contacted with a request to obtain the required data. We contacted 11 authors for further information and of these, two responded with data that could be used in the analysis (Katona et al. 2012; Raskin et al. 2007) .
Each outcome (i.e. cognitive test score) was allocated to one of the following cognitive domains -immediate memory (i.e. learning), recent memory (i.e. free recall, cued recall and recognition), very long term memory (i.e. semantic, autobiographical and implicit learning), expressive language (i.e. naming, word finding, fluency, grammar and syntax), receptive language, sustained attention, divided attention, selective attention, processing speed, visual perception, visuospatialconstructional skills, perceptual motor, working memory or executive function. These cognitive domains are based on the Diagnostic and Statistical manual of the American Psychiatric Association (APA) 5th Edition (DSM-5) neurocognitive domains (APA 2013). Cognitive tests were allocated to each cognitive domain based on the primary cognitive function it was designed to measure, or the domain that it is commonly used to measure in neuropsychological practice. Strauss et al. (2006) and Lezak et al. (2012) were used as guides, and test allocation also conforms to the evidencebased practice guidelines developed by Daffner et al. (2015) . Final test allocation decisions were reviewed by and agreed to by consensus of all authors. A summary of the cognitive domains examined, the tests allocated within those domains, the outcome measure employed, and associated references to support the allocations is presented in Table 1 .
To ensure that each study did not contribute more than one effect size to the pooled effect, only one effect size per cognitive domain was entered into the analysis. An exception to this occurred if a single study examined more than one antidepressant drug, in which case one effect size per subgroup (drug) was included in the analysis. Because a multiplicity of outcome data was expected to occur in some studies, as recommended by Tendal et al. (2009) , a hierarchy of measurement instruments was developed a priori that gave preference to neuropsychological tests most commonly in use. For studies that presented data for more than one test per cognitive domain, a single test per cognitive domain was selected based on this hierarchy. Care was taken to ensure that the scores for a given test provided independent measures of performance. Thus, sub-scores and total scores from a test could not both be used in the calculation of an effect size.
Effect sizes were calculated in a multi-stage process. The first stage involved calculating effect sizes for each test that was included from each individual study. In most cases, higher cognitive test scores indicated better performance by the treatment group (i.e. antidepressant group) compared to the control group (i.e. placebo group), or better performance after the administration of antidepressants in pre-post studies. Therefore, a positive effect size indicates that antidepressant drug users performed better than controls, or participant's scores improved following drug administration. In cases where a higher score indicated poorer test performance than a lower score (e.g., number of errors, timed tasks), the direction of the effect sizes for these scores were transformed so that a positive effect size still indicated better performance in the antidepressant users.
The calculation of effect size for each outcome, pooling of effect sizes and tests of heterogeneity were conducted using Comprehensive Meta-Analysis Software (CMA). Given that the studies included in the meta-analyses differed in terms of several variables (e.g., drug type, length of use, participant characteristic etc.), a random effects model was employed to calculate the pooled effect for each cognitive domain. As noted by Borenstein et al. (2010) , the random effects model is often the most appropriate model to use in a quantitative synthesis of existing literature because the fixed-effect model is based on the assumption that all studies in the meta-analysis share a common (true) effect size. Conversely, the random-effects model allows that the true effect size may vary from study to study. Pooled effect sizes were calculated separately for each cognitive domain, for which there were two or more effect sizes. This allowed for pooled effects in the domains of divided attention, executive function, expressive language, immediate memory, perceptual motor skills, processing speed, recent memory, sustained attention, visuospatial-constructional skills and working memory. Studies were subsequently systematically removed from the pooled sample to determine if removal of any one specific agent or study could significantly alter the overall effect size. Homogeneity in effect sizes was tested using the Q statistic (Chi 2 ) for each cognitive domain. Heterogeneity was quantified using the I 2 statistic, where 25% = low, 50% = moderate, and 75% = high heterogeneity (Higgin et al. 2003) . To explore heterogeneity, the effects of several moderator variables were investigated including study design, participant age, participant health status and length of drug use.
Risk of Bias
Risk of bias was assessed for all studies included in the metaanalysis by two review authors (CP and SW). Disagreements were resolved by discussion between the two review authors. If no agreement could be reached, it was planned that the third author would decide. The risk of bias tool used was developed by the Cochrane Effective Practice and Organisation of Care group (EPOC 2015) and was selected as it is designed to assess a range of study methodologies including RCTs, nonrandomised controlled trials (NRCTs) and controlled before and after studies. The nine standard criteria were used to assess the risk of bias for all included studies, namely, allocation sequence generation and concealment, measurement and comparability of baseline characteristics, incomplete (missing) data, blinding, contamination, selective outcome reporting and other risk of bias. Studies were designated low risk for a given category if the authors described protocols to protect against risk of bias, or if appropriate methods were used to mitigate the noted risk (e.g. if groups were found to be imbalanced at baseline, but appropriate adjusted analysis was performed to control for this, studies were denoted low risk). Studies were designated to be at high risk if the described protocols were concerning for bias in a given domain. If insufficient information was provided in the paper to determine risk of bias, studies were denoted as of unclear risk. Note that all NRCT's and controlled before and after studies were denoted as not applicable (NA) for allocation sequence generation and concealment. As recommended by the Cochrane Review Handbook, a funnel plot was created to assess for publication bias, sometimes referred to as small sample bias, for all included studies. An Egger's test was used to quantitatively assess for plot asymmetry.
Results
The literature search of electronic databases yielded a total of 4932 potentially relevant articles ( Fig. 1 ). An additional 76 records were identified from additional sources. Titles and abstracts were screened, yielding a total of 172 articles for full text review. Of these, 33 articles were included in the meta-analysis. The relevant demographic information for each study, including the cognitive domains studied and the neuropsychological tests used to examine these domains, is presented in Table 2 .
As previously stated, pooled effect sizes were calculated when two or more studies contributed an effect size to that particular domain. Thus, pooled effect sizes were calculated for the cognitive domains of divided attention, executive function, expressive language, immediate memory, perceptual motor skills, processing speed, recent memory, sustained attention, visuospatial-constructional skills and working memory. Summary data for all studies included in the meta-analysis is presented in Table 3 . In order to investigate the effects of the different classes of antidepressants on cognition for depressed versus non-depressed persons, a subgroup analysis comparing the various classes of antidepressants was conducted for depressed and non-depressed participants for each cognitive domain. Two studies Gallassi et al. 2006) included participants who were treated with more than one class of antidepressant (i.e. some participants were treated with an SSRI and others were treated with a TCA). The antidepressant class for these studies was denoted as 'mixed.'
Divided Attention
Eight studies examined the effects of antidepressant use on divided attention for depressed participants (Culang-Reinlieb et al. 2012; Fann et al. 2001; Herrera-Guzman et al. 2010; Mahableshwarkar et al. 2015; McIntyre et al. 2014; Talarowska et al. 2010; Vythilingam et al. 2004; Wroolie et al. 2006) . Of these studies, three evaluated two Insufficient data provided to calculate effect size (n = 11) Non standardized / modified tests used to assess cognition (n = 56) Insufficient data provided on protocol / methodology / results to determine eligibility for inclusion / conduct ROB etc. (n = 16) Clear potential confounding effect of drugs other than target antidepressant / 'add on' study (n = 9) Study methodology (e.g., case study, cross sectional, lacked comparison group or baseline data etc.) (n = 18) Did not examine effect of one of the target antidepressant drugs on cognition (n = 18) Did not report results for one or more cognitive domain (i.e. only composite score provided) (n = 6) Data reported elsewhere / already included (n = 5)
Studies included in meta analysis (n = 33)
Records screened and duplicates removed (n = 5,008)
Records identified through database searching (n = 4,932) antidepressant drugs in parallel, providing a total of 11 independent effect sizes to pool, including evaluation of SMS's, SNRI's, SSRI's and TCA's. As shown in Fig. 2a , overall, the antidepressants had a small but statistically significant positive effect on divided attention for depressed persons (Hedges' g = 0.21, 95% CI = 0.00 to 0.42, z = 1.96, p = 0.05). Heterogeneity was low, Tau 2 = 0.02; Chi 2 = 19.53, df = 10 (p = 0.03), I 2 = 48.81%. Comparisons between antidepressant class revealed that SMS's, SNRI's and SSRI's all had small but statistically significant positive effects on divided attention, while TCA's had a small, negative, statistically non-significant effect (see Fig. 2a ). The pooled effect sizes between these four antidepressant classes were significantly statistically different from each other, Chi 2 = 13.17, df = 3 (p = 0.01). Five studies examined the effects of antidepressant use on divided attention for non-depressed participants (Banos et al. 2010; Jorge et al. 2010; Mohs et al. 2012; Nielen and Den Boer 2003; Schmitt et al. 2002) . Each study contributed one effect size to the analysis and evaluated SNRI's and SSRI's.
As shown in Fig. 2b , overall, antidepressants had a statistically non-significant effect on divided attention for non-depressed persons (Hedges' g = 0.03, 95% CI = −0.33 to 0.39, z = 0.15, p = 0.88). Heterogeneity was low, Tau 2 < 0.01; Chi 2 = 3.53, df = 4 (p = 0.48), I 2 < 0.01%. Comparisons between antidepressant classes revealed that SMS's had a small, negative, statistically non-significant effect on divided attention while SSRI's had a small, positive, statistically non-significant effect (see Fig. 2b ). A comparison of the pooled effect sizes of these two antidepressant classes were not statistically significantly different from each other, Chi 2 = 2.72, df = 3 (p = 0.10).
Executive Function
Six studies examined the effects of antidepressant use on executive function for depressed participants (Boggio et al. 2005; Butters et al. 2000; Devanand et al. 2003; Greer et al. 2014; Herrera-Guzman et al. 2010; Nickel et al. 2003) . Of these studies, two evaluated two antidepressant drugs in Fig. 2 a. Pooled effect (random effects model) for studies assessing the effects of antidepressants on divided attention for depressed participants, grouped by antidepressant drug class. b. Pooled effect (random effects model) for studies assessing the effects of antidepressants on divided attention for non-depressed participants, grouped by antidepressant drug class parallel, providing a total of eight independent effect sizes to pool, including evaluation of mixed antidepressants, SNRI's, SSRE's and SSRI's. As shown in Fig. 3a , overall, antidepressants had a small but statistically significant positive effect on executive function for depressed persons (Hedges' g = 0.28, 95% CI = 0.13 to 0.44, z = 3.45, p < 0.01). Heterogeneity was low, Tau 2 < 0.01; Chi 2 = 5.95, df = 7 (p = 0.55), I 2 < 0.01%. Comparisons between antidepressant classes revealed that SNRI's and SSRI's had small, but statistically significant, positive effects on executive function, while the mixed class and SSRE's had non-significant effects (see Fig. 3a) . A comparison of the pooled effect sizes for the four antidepressant classes were not statistically significantly different from each other, Chi 2 = 0.33, df = 3 (p = 0.95). Four studies examined the effects of antidepressant use on executive function for non-depressed participants (Banos et al. 2010; Jorge et al. 2010; Lochner et al. 2016; Nielen and Den Boer 2003) . Each study contributed one effect size to the analysis and evaluated only SSRI's. As shown in Fig. 3b , overall, antidepressants had a small, negative, statistically non-significant effect on executive function for nondepressed persons (Hedges' g = −0.14, 95% CI = −0.37 to 0.08, z = −1.25, p = 0.21). Heterogeneity was low, Tau 2 < 0.01; Chi 2 = 3.11, df = 3 (p = 0.38), I 2 < 0.01%.
Expressive Language
Five studies examined the effects of antidepressant use on expressive language for depressed participants (Boggio et al. 2005; Butters et al. 2000; Devanand et al. 2003; Fann et al. 2001; Wroolie et al. 2006) . Each study contributed one effect size to the analysis and evaluated mixed antidepressants and SSRI's. As shown in Fig. 4a , overall, antidepressants had a small, positive, statistically non-significant effect on expressive language for depressed persons (Hedges' g = 0.15, 95% CI = −0.03 to 0.33, z = 1.63, p < 0.10). Heterogeneity was low, Tau 2 = 0.00; Chi 2 = 2.14, df = 4 (p = 0.71), I 2 = 0.00%. Comparisons between antidepressant classes revealed that both the mixed class of antidepressants and SSRI's had a small, positive, statistically non-significant effects on expressive language (see Fig. 3a ). The pooled effect sizes of the four antidepressant classes were not statistically significantly different from each other, Chi 2 = 0.38, df = 1 (p = 0.54). Only one study investigated the effects of antidepressants on expressive language for non-depressed participants (Jorge et al. 2010: see Fig. 4b ). This study investigated SSRI's and found a small, positive, statistically non-significant effect of antidepressants on expressive language (Hedges' g = 0.13, 95% CI = −0.29 to 0.55, z = 0.62, p = 0.54).
Immediate Memory
Fourteen studies examined the effects of antidepressant use on immediate memory for depressed participants (CulangReinlieb et al. 2012; Culang et al. 2009; Devanand et al. 2003; Doraiswamy et al. 2003; Fann et al. 2001; Greer et al. 2014; Katona et al. 2012; McIntyre et al. 2014; Munro et al. 2004; Nickel et al. 2003; Raskin et al. 2007; Talarowska et al. 2010; Vythilingam et al. 2004; Wroolie et al. 2006) . Of these studies, five evaluated two antidepressant drugs in parallel, providing a total of 19 independent effect sizes to pool, including evaluation of SMS's, SNRI's, SSRE's, SSRI's and TCA's. As shown in Fig. 5a , overall, antidepressants had a small but statistically significant positive effect on immediate memory for depressed persons (Hedges' g = 0.22, 95% CI = 0.05 to 0.39, z = 2.56, p = 0.01). Heterogeneity was moderate, Tau 2 = 0.05; Chi 2 = 59.48, df = 18 (p < 0.01), I 2 = 69.74%. Comparisons between antidepressant classes revealed that SSRI's had a small but statistically significant positive effect on immediate memory, while SMS', SNRI's, SSRE's and TCA's all had statistically non-significant effects (see Fig. 5a ). The pooled effect sizes of these four antidepressant classes were not statistically significantly different from each other, Chi 2 = 2.64, df = 4 (p = 0.62). Five studies examined the effects of antidepressant use on immediate memory for non-depressed participants (Banos et al. 2010; Jorge et al. 2010; Kalechstein et al. 2013; Mohs et al. 2012; Mowla et al. 2007b ). Each study contributed one effect size to the analysis and evaluated SNRI's and SSRI's. As shown in Fig. 5b , overall, antidepressants had a small, positive, statistically non-significant effect on immediate memory for nondepressed persons (Hedges' g = 0.15, 95% CI = −0.16 to 0.46, z = 0.97, p = 0.33). Heterogeneity was low, Tau 2 = 0.03; Chi 2 = 6.08, df = 4 (p = 0.19), I 2 = 34.20%. Comparisons between antidepressant classes revealed that both SNRI's and SSRI's had positive, statistically non-significant effects on immediate memory (see Fig. 5b ). The pooled effect sizes between these two antidepressant classes were not statistically significantly different from each other, Chi 2 = 0.04, df = 1 (p = 0.85).
Perceptual Motor Skills
Two studies examined the effects of antidepressant use on perceptual motor skills for depressed participants (Culang- Fig. 4 a. Pooled effect (random effects model) for studies assessing the effects of antidepressants on expressive language for depressed participants, grouped by antidepressant drug class. b. Pooled effect (random effects model) for studies assessing the effects of antidepressants on expressive language for non-depressed participants Reinlieb et al. 2012; Fann et al. 2001) . Of these studies, one evaluated two antidepressant drugs in parallel, providing a total of three independent effect sizes to pool, including evaluation of SSRI's and TCA's. As shown in Fig. 6a , overall, antidepressants had a small, positive, statistically nonsignificant effect on perceptual motor skills for depressed persons (Hedges' g = 0.16, 95% CI = −0.21 to 0.53, z = 0.86, p = 0.39). Heterogeneity was low, Tau 2 = 0.01; Chi 2 = 2.43, df = 2 (p = 0.30), I 2 = 17.75%. Comparisons between antidepressant classes revealed that both SSRI's and TCA's had a small but statistically non-significant effects on perceptual motor skills (see Fig. 6a ). The pooled effect sizes of these two antidepressant classes were not statistically significantly different from each other, Chi 2 = 0.01, df = 1 (p = 0.94). Only one study investigated the effects of antidepressants on perceptual motor skills for non-depressed participants (Loubinoux et al. 2005 : see Fig. 6b ). This study investigated SSRI's and found a small, positive, statistically non-significant effect of antidepressants on perceptual motor skills (Hedges' g = 0.52, 95% CI = −0.13 to 1.17, z = 1.57, p = 0.12).
Processing Speed
Ten studies examined the effects of antidepressant use on processing speed for depressed participants (Culang et al. 2009; Devanand et al. 2003; Doraiswamy et al. 2003; Fann et al. 2001; Finkel et al. 1999; Katona et al. 2012; Levkovitz et al. 2002; Mahableshwarkar et al. 2015; McIntyre et al. 2014; Raskin et al. 2007) . Of these studies, six evaluated two antidepressant drugs in parallel, providing a total of 16 independent effect sizes to pool, including evaluation of SMS's, SNRI's, SSRI's and TCA's. As shown in Fig. 7a , overall, antidepressants had a small but statistically significant positive effect on processing speed for depressed persons (Hedges' g = 0.23, 95% CI = 0.06 to 0.39, z = 2.71, p = 0.01). Heterogeneity was moderate, Tau 2 = 0.03; Chi 2 = 40.39, df = 15 (p < 0.01), I 2 = 62.86%. Comparisons between antidepressant classes revealed that SMS's and SSRI's had small but statistically significant positive effects on processing speed, while SNRI's and TCA's had statistically non-significant effects (see Fig. 5a ). The pooled effect sizes between these four antidepressant classes were not statistically significantly different from each other, Chi 2 = 6.06, df = 3 (p = 0.11).
Four studies examined the effects of antidepressant use on processing speed for non-depressed participants (Banos et al. 2010; Karsten et al. 2017; Lee et al. 2005; Mohs et al. 2012) . Each study contributed one effect size to the analysis and evaluated NaSSA's, SNRI's and SSRI's. As shown in Fig. 7b , overall, antidepressants had a small, negative, statistically nonsignificant effect on processing speed for non-depressed persons (Hedges' g = −0.11, 95% CI = −0.37 to 0.16, z = −0.79, p = 0.43). Heterogeneity was low, Tau 2 = 0.00; Chi 2 = 0.63, df = 3 (p = 0.89), I 2 = 0.00%. Comparisons between antidepressant classes revealed that NaSSA's, SNRI's and SSRI's had negative, statistically non-significant effects on processing speed (see Fig. 7b ). The pooled effect sizes between these three antidepressant classes were not statistically significantly different from each other, Chi 2 = 0.58, df = 2 (p = 0.75).
Recent Memory
Fifteen studies examined the effects of antidepressant use on recent memory for depressed participants Devanand et al. 2003; Doraiswamy et al. 2003; Fann et al. 2001; Gallassi et al. 2006; Greer et al. 2014; Katona et al. 2012; Levkovitz et al. 2002; McIntyre et al. 2014; Munro et al. 2004; Nickel et al. 2003; Raskin et al. 2007; Talarowska et al. 2010; Vythilingam et al. 2004; Wroolie et al. 2006) . Of these studies, five evaluated two antidepressant drugs in parallel, providing a total of 20 independent effect sizes to pool, including evaluation of mixed antidepressants, SMS's, SNRI's, SSRE's, SSRI's and TCA's. As shown in Fig. 8a , overall, antidepressants (random effects model) for studies assessing the effects of antidepressants on perceptual motor skills for non-depressed participants had a small but statistically significant positive effect on recent memory for depressed persons (Hedges' g = 0.18, 95% CI = 0.03 to 0.33, z = 2.37, p = 0.02). Heterogeneity was small, Tau 2 = 0.02; Chi 2 = 33.73, df = 19 (p = 0.02), I 2 = 43.68%. Comparisons between antidepressant classes revealed that mixed antidepressants, SMS's, SNRI's and SSRI's had small but statistically significant positive effects on recent memory, while SSRE's and TCA's had negative, statistically non-significant effects (see Fig. 8a ). The pooled effect sizes between these six antidepressant classes were statistically significantly different from each other, Chi 2 = 12.60, df = 5 (p = 0.03). Seven studies examined the effects of antidepressant use on recent memory for non-depressed participants (Banos et al. 2010; Fani et al. 2009; Jorge et al. 2010; Kalechstein et al. 2013; Mohs et al. 2012; Mowla et al. 2007a, b; Nielen and Den Boer 2003) . Each study contributed one effect size to the analysis and evaluated SNRI's and SSRI's. As shown in Fig.   8b , overall, antidepressants had a statistically non-significant effect on recent memory for non-depressed persons (Hedges' g = 0.01, 95% CI = −0.32 to 0.34, z = −0.06, p = 0.95). Heterogeneity was moderate, Tau 2 = 0.11; Chi 2 = 16.15, df = 6 (p = 0.01), I 2 = 62.84%. Comparisons between the antidepressant classes revealed that both SNRI's and SSRI's had statistically non-significant effects on recent memory (see Fig. 8b ). The pooled effect sizes between these two antidepressant classes were not statistically significantly different from each other, Chi 2 = 0.62, df = 1 (p = 0.43).
Sustained Attention
Twelve studies examined the effects of antidepressant use on sustained attention for depressed participants (Boggio et al. 2005; Butters et al. 2000; Culang-Reinlieb et al. 2012; Fann et al. 2001; Gallassi et al. 2006; Greer et al. 2014 ; Herrera- Fig. 7 a. Pooled effect (random effects model) for studies assessing the effects of antidepressants on processing speed for depressed participants, grouped by antidepressant drug class. b. Pooled effect (random effects model) for studies assessing the effects of antidepressants on processing speed for non-depressed participants, grouped by antidepressant drug class Guzman et al. 2010; Levkovitz et al. 2002; Mahableshwarkar et al. 2015; McIntyre et al. 2014; Vythilingam et al. 2004; Wroolie et al. 2006) . Of these studies, four evaluated two antidepressant drugs in parallel, providing a total of 16 independent effect sizes to pool, including evaluation of mixed antidepressants, SMS's, SNRI's, SSRI's and TCA's. As shown in Fig. 9a , overall, antidepressants had a small but statistically significant positive effect on sustained attention for depressed persons (Hedges' g = 0.19, 95% CI = 0.07 to 0.32, z = 3.07, p < 0.01). Heterogeneity was small, Tau 2 = 0.01; Chi 2 = 21.63, df = 15 (p = 0.12), I 2 = 30.66%. Comparisons between antidepressant classes revealed that only mixed antidepressants had a small but statistically significant positive effect on sustained attention, while SMS's, SNRI's, SSRI's and TCA's had statistically non-significant effects (see Fig. 9a ). The pooled effect sizes between these five antidepressant classes were not statistically significantly different from each other, Chi 2 = 1.23, df = 4 (p = 0.86). Five studies examined the effects of antidepressant use on sustained attention for non-depressed participants (Banos et al. 2010; Jorge et al. 2010; Kalechstein et al. 2013; Mohs et al. 2012; Nielen and Den Boer 2003) . Each study contributed one effect size to the analysis and evaluated SNRI's and SSRI's. As shown in Fig. 9b , overall, antidepressants had a Fig. 8 a. Pooled effect (random effects model) for studies assessing the effects of antidepressants on recent memory for depressed participants, grouped by antidepressant drug class. b. Pooled effect (random effects model) for studies assessing the effects of antidepressants on recent memory for non-depressed participants, grouped by antidepressant drug class negative, statistically non-significant effect on sustained attention for non-depressed persons (Hedges' g = −0.18, 95% CI = −0.38 to 0.02, z = −1.80, p = 0.07). Heterogeneity was low, Tau 2 = 0.00; Chi 2 = 2.26, df = 4 (p = 0.69), I 2 = 0.00%. Comparisons between antidepressant classes revealed that both SNRI's and SSRI's had statistically non-significant effects on recent memory (see Fig. 9b ). The pooled effect sizes between these two antidepressant classes were not statistically significantly different from each other, Chi 2 = 0.34, df = 1 (p = 0.56).
Visuospatial-Constructional Skills
Three studies examined the effects of antidepressant use on visuospatial-constructional skills for depressed participants (Boggio et al. 2005; Butters et al. 2000; Munro et al. 2004 ).
Each study contributed one effect size to the analysis which evaluated mixed antidepressants and SSRI's. As shown in Fig. 10a , overall, antidepressants had a small, negative, statistically non-significant effect on visuospatial-constructional skills for depressed persons (Hedges' g = −0.14, 95% CI = −0.51 to 0.24, z = −0.70, p = 0.48). Heterogeneity was small, Tau 2 = 0.00; Chi 2 = 1.94, df = 2 (p = 0.38), I 2 = 0.00%. Comparisons between antidepressant classes revealed that both mixed antidepressants and SSRI's had a small, statistically non-significant effect on visuospatial-constructional skills (see Fig. 10a ). The pooled effect sizes for these two antidepressant classes were not statistically significantly different from each other, Chi 2 = 0.09, df = 1 (p = 0.76). Only one study investigated the effects of antidepressants on visuospatial-constructional skills for non-depressed participants (Jorge et al. 2010 : see Fig. 10b ). This study investigated Fig. 9 a. Pooled effect (random effects model) for studies assessing the effects of antidepressants on sustained attention for depressed participants, grouped by antidepressant drug class. b. Pooled effect (random effects model) for studies assessing the effects of antidepressants on sustained attention for non-depressed participants, grouped by antidepressant drug class SSRI's and found a small, negative, statistically nonsignificant effect of antidepressants on visuospatialconstructional skills (Hedges' g = −0.11, 95% CI = −0.53 to 0.31, z = −0.52, p = 0.60).
Working Memory
Nine studies examined the effects of antidepressant use on working memory for depressed participants (Boggio et al. 2005; Devanand et al. 2003; Gallassi et al. 2006; Greer et al. 2014; Herrera-Guzman et al. 2010; Mahableshwarkar et al. 2015; Raskin et al. 2007; Vythilingam et al. 2004; Wroolie et al. 2006) . Of these studies, two evaluated two antidepressant drugs in parallel, providing a total of 11 independent effect sizes to pool, including evaluation of mixed antidepressants, SMS's, SNRI's and SSRI's. As shown in Fig. 11a , overall, antidepressants had a small, positive, statistically nonsignificant effect on working memory for depressed persons (Hedges' g = 0.07, 95% CI = −0.06 to 0.20, z = 1.10, p = 0.27). Heterogeneity was small, Tau 2 = 0.00; Chi 2 = 11.07, df = 10 (p = 0.35), I 2 = 9.67%. Comparisons between antidepressant classes revealed that mixed antidepressants, SMS's, SNRI's and SSRI's all had a small, statistically non-significant effects on working memory (see Fig. 11a ). The pooled effect sizes for these four antidepressant classes were not statistically significantly different from each other, Chi 2 = 0.04, df = 3 (p = 0.10).
Four studies examined the effects of antidepressant use on working memory for non-depressed participants (Banos et al. 2010; Kalechstein et al. 2013; Mowla et al. 2007a Mowla et al. , 2007b Nielen and Den Boer 2003) . Each study contributed one effect size to the analysis and evaluated SSRI's only. As shown in Fig. 11b , overall, antidepressants had a small, positive, statistically non-significant effect on working memory for nondepressed persons (Hedges' g = 0.04, 95% CI = −0.21 to 0.29, z = 0.31, p = 0.77). Heterogeneity was low, Tau 2 = 0.00; Chi 2 = 1.00, df = 3 (p = 0.80), I 2 = 0.00%.
Additional Moderator Analyses
In order to investigate the potential impact of study design on the overall pooled effect of antidepressants on cognition, two meta-analyses were carried out which pooled the effect sizes across all cognitive domains for depressed and non-depressed participants. In order to ensure that each study did not contribute more than one effect size per antidepressant, where one study contributed more than one effect size (i.e. cognitive domain), the mean of those effect sizes was entered into the analysis. A subgroup analysis was then conducted comparing randomised controlled trials (RCT's), controlled before and after studies, and uncontrolled pre-post studies. For depressed participants, the analysis revealed that overall, antidepressants had a small, positive, statistically significant effect on this combined measure of cognitive function (Hedges' g = 0.22, 95% CI = 0.16 to 0.28, z = 7.47, p < 0.01), which is comparable to the findings from individual cognitive domains. Heterogeneity was small, Tau 2 = 0.00; Chi 2 = 31.71, df = 29 (p = 0.35), I 2 = 9.67%. Six RCT's effect (random effects model) for studies assessing the effects of antidepressants on visuospatial/constructional skills for non-depressed participants investigated depressed participants. Of these, two evaluated two antidepressant drugs in parallel, providing a total of eight independent effect sizes to pool. The sub-group analysis revealed a small, positive, statistically significant effect for all antidepressants versus placebo for the RCT's (Hedges' g = 0.19, 95% CI = 0.10 to 0.29, z = 4.03, p < 0.01). Ten controlled before and after studies investigated depressed participants. Of these, seven evaluated two antidepressant drugs in parallel, providing a total of 17 independent effect sizes to pool. The sub-group analysis revealed a small, positive, statistically significant effect for antidepressants on cognition (Hedges' g = 0.25, 95% CI = 0.17 to 0.33, z = 6.01, p < 0.01). Five pre-post studies investigated depressed participants, and each study contributed one effect size to the analysis, providing five independent effect sizes to pool. The subgroup analysis revealed a small, positive, statistically significant effect for antidepressants on cognition (Hedges' g = 0.19, 95% CI = 0.01 to 0.38, z = 2.06, p = 0.04). Results from the three included study designs were not significantly different from each other, Chi 2 = 0.80, df = 2 (p = 0.67). For non-depressed participants, the analysis revealed that overall, antidepressants had a small, positive, statistically nonsignificant effect on this combined measure of cognitive function (Hedges' g = 0.01, 95% CI = −0.14 to 0.16, z = 0.08, p = 0.94), which is comparable to the findings from individual cognitive domains. Heterogeneity was small, Tau 2 = 0.00; Chi 2 = 10.93, df = 11 (p = 0.45), I 2 = 0.00%. Eight RCT's investigated non-depressed participants and each study contributed one effect size to the analysis, providing eight independent effect sizes to the pool. The sub-group analysis revealed a small, positive, statistically non-significant effect for all antidepressants versus placebo for the RCT's (Hedges' g = 0.06, 95% CI = −0.14 to 0.26, z = 0.56, p = 0.58). Four controlled before and after studies investigated non-depressed participants and each study contributed one effect size to the analysis, providing four independent effect sizes to pool. The sub-group analysis revealed a small, negative, statistically non-significant effect for antidepressants on cognition (Hedges' g = −0.06, 95% CI = −0.28 to 0.17, z = −0.50, p = 0.62). Results from the two included study designs were not significantly different from each other, Chi 2 = 0.55, df = 1 (p = 0.46).
Given that the studies included in the meta-analysis investigated cognition in participants of varying ages, a random effects meta-regression analysis was applied to estimate the Fig. 11 a. Pooled effect (random effects model) for studies assessing the effects of antidepressants on working memory for depressed participants, grouped by antidepressant drug class. b. Pooled effect (random effects model) for studies assessing the effects of antidepressants on working memory for non-depressed participants relationship between Hedges' g and the mean age of participants in each study. The meta-regression revealed that age was not significantly related to the overall pooled effect size, QModel was 1.05 with df = 1 and p = 0.31. Although the coefficient for age was positive (0.002), indicating that Hedges' g increased with age, only 1% of the variance in true effects could be explained by age alone, R 2 analog = 0.01. Because age may potentially represent an important moderator variable, a further stratified analysis was undertaken comparing studies which examined participants with a mean age of 60 years or under (20 studies with 24 total effect sizes) to studies which examined participants with a mean age greater than 60 years (13 studies with 18 total effect sizes). A subgroup analysis was conducted comparing depressed and non-depressed participants aged 60 years and under. The analysis revealed a small, positive, statistically significant effect of antidepressants on cognition for depressed participants (Hedges' g = 0.23, 95% CI = 0.14 to 0.32, z = 5.13, p < 0.01) and a small, negative, statistically non-significant effect of antidepressants on cognition for non-depressed participants (Hedges' g = −0.02, 95% CI = −0.18 to 0.14, z = −0.22, p = 0.83). Heterogeneity for the 60 and under group was found to be low, Tau 2 = 0.00; Chi 2 = 22.36, df = 23 (p = 0.50); I 2 = 0.0%. A further subgroup analysis was conducted comparing depressed and non-depressed participants aged over 60 years. The analysis revealed a small, positive, statistically significant effect of antidepressants on cognition for depressed participants (Hedges' g = 0.21, 95% CI = 0.12 to 0.30, z = 4.51, p < 0.01) and a small, positive, statistically non-significant effect of antidepressants on cognition for non-depressed participants (Hedges' g = 0.12, 95% CI = −0.26 to 0.50, z = 0.63, p = 0.53). Heterogeneity for the over 60 group was found to be low, Tau 2 = 0.01; Chi 2 = 27.18, df = 17 (p = 0.06); I 2 = 37.46%. Given that the included studies investigated the effects of antidepressants across various time frames, length of drug use (in days) was investigated as a moderator variable using a random effects meta-regression analysis. The metaregression revealed that length of antidepressant use was not significantly related to the overall pooled effect size, Q-Model was 0.37 with df = 1 and p = 0.55. Less than 1% of the variance in true effects could be explained by length of drug use alone, R 2 analog = <0.001. Lastly, the studies included in the analysis comprised a variety of patient groups (i.e. healthy, depressed, cocaine dependent, post stroke etc.). In order to investigate the potential impact that these different health conditions may have on the results, each study was grouped according to one of the following categories -healthy, degenerative neurological condition (e.g., mild cognitive impairment, dementia plus depression, Parkinson's disease and depression etc.), stable neurological condition (e.g., post-stroke, traumatic brain injury) or psychiatric (e.g., depression, obsessive compulsive disorder, post-traumatic stress disorder etc.). A subgroup analysis was conducted comparing the four participant groups as described above. The analysis revealed a small, positive, statistically non-significant effect of antidepressants on cognition for the three studies which investigated healthy participants (Hedges' g = 0.21, 95% CI = −0.11 to 0.52, z = 1.28, p = 0.20), a small, positive, statistically significant effect of antidepressants on cognition for the 10 studies that investigated participants with a degenerative neurological condition (Hedges' g = 0.28, 95% CI = 0.16 to 0.40, z = 4.67, p < 0.01), a small, positive, statistically non-significant effect for the five studies that investigated participants with a stable neurological condition (Hedges' g = 0.07, 95% CI = −0.16 to 0.30, z = 0.63, p = 0.53), and a small, positive, statistically significant effect for the 15 studies that investigated participants with a psychiatric condition (Hedges' g = 0.17, 95% CI = 0.10 to 0.24, z = 4.66, p < 0.01). Heterogeneity was low in the degenerative neurological, stable neurological and psychiatric conditions with 
Bias of Included Studies
The assessment of bias is summarised in Table 4 . None of the included studies were found to present a high risk of bias for sequence generation, sequence concealment, baseline outcomes, baseline characteristics, contamination or selective outcome reporting, however several studies did present an unclear risk for these categories. Two studies (Banos et al. 2010; Butters et al. 2000) presented a high risk of bias for incomplete outcome data. Five studies (Devanand et al. 2003; Fann et al. 2001; Nielen and Den Boer 2003; Vythilingam et al. 2004; Wroolie et al. 2006) were denoted as high risk for blinding. Given that several of the included studies were noted to have a high risk of bias in one or more categories, a stratified analysis was undertaken which compared depressed and nondepressed participants in studies which were found to present a high risk of bias in at least one category (seven studies with seven total effect sizes) to studies which were deemed to have a low or unclear risk of bias (26 studies with 35 total effect sizes). For studies with a high risk of bias, the analysis revealed that for depressed participants, antidepressants had a small, positive, statistically significant effect on cognitive functioning (Hedges' g = 0.19, 95% CI = 0.01 to 0.37, z = 2.11, p = 0.04). For non-depressed participants antidepressants had a small, negative, statistically non-significant effect on cognitive functioning (Hedges' g = −0.07, 95% CI = −0.41 to 0.28, z = −0.38, p = 0.71). Heterogeneity was small, Tau 2 = 0.00, Chi 2 = 5.38, df = 6 (p = 0.50), I 2 = 0.00%. For studies with a low or unclear risk of bias, the analysis revealed that for depressed participants antidepressants had a small, positive, statistically significant effect on cognitive functioning (Hedges' g = 0.22, 95% CI = 0.16 to 0.29, z = 6.93, p < 0.01). For non-depressed participants antidepressants had Note: CBA, controlled before and after study; NA, not applicable; Pre-post, pre-and post-testing; RCT, randomised controlled trial a small, positive, statistically non-significant effect on cognitive functioning (Hedges' g = 0.14, 95% CI = −0.06 to 0.33, z = 0.26, p = 0.79). Heterogeneity was small, Tau 2 = 0.00, Chi 2 = 31.71, df = 29 (p = 0.33), I 2 = 8.55%. Small sample bias was assessed using a funnel plot as indicated in Fig. 12 . Qualitative assessment of the funnel plot revealed no obvious signs of publication bias. As recommended by the Cochrane Review Handbook an Egger's test was used to test for funnel plot asymmetry and found the intercept (b) to be −0.72, with a 95% confidence interval from −1.57 to 0.12, and a one-tailed p-value of 0.09, indicating the plot is symmetrical.
Discussion
This meta-analysis identified 33 studies that examined the effects of antidepressants on cognitive function. The studies investigated these effects using a range of participant groups and multiple antidepressant drugs. When studies were analysed separately based on the depression status of their participants (depressed versus non-depressed), antidepressants were found to have a positive effect on divided attention, executive function, immediate memory, processing speed, recent memory and sustained attention for depressed persons only. Antidepressants had no significant effect on the cognitive function of non-depressed persons across any of the cognitive domains analysed. Heterogeneity varied across the cognitive domains assessed, but fell within the low to moderate ranges. Additional analyses of study design, participant age and length of antidepressant use did not reveal significant relationships between any of these variables and the effects of antidepressants on cognition.
The analysis revealed a clear delineation between depressed and non-depressed participant groups, and aligns with previous research which suggests that for people with depression, antidepressants tend to have a modest but positive effect on some domains of cognition (Baune and Renger 2014; Boggio et al. 2005; Keefe et al. 2014; Rosenblat et al. 2015) . Our findings are also consistent with previous research in healthy samples (Repantis et al. 2009 ), which suggests that the newer generation antidepressants neither enhance nor compromise cognition in non-depressed persons.
Some researchers have argued that the positive effect of antidepressants on cognitive performance for depressed persons is secondary to the amelioration of mood symptoms, which subsequently improves motivation, self-monitoring and planning (Austin et al. 2001) . Given that deficits in memory, attention, executive function and processing speed are most commonly reported to be experienced by depressed persons (Goodwin 1997; Liotti and Mayberg 2001; Rock et al. 2014) , the modest positive effect of antidepressants across these domains for depressed participants in the current study adds weight to this suggestion.
Another possibility, proposed by Harmer et al. (2009) , is that at the neuropsychological level, antidepressants remediate negative affective biases in depressed persons. The authors suggest that these changes in affective biases do not directly enhance mood, but rather enable subsequent cognitive and psychological reconsolidation. Over time this effect could lead to greater reactivity and improvement in mood, as well as decreased social and occupational withdrawal. Harmer et al. (2009) suggests that changes in affective biases ultimately free up cognitive processing resources which in turn improve memory, attention and executive function skills.
Alternatively, it could be suggested that changes in the monoaminergic systems affected by antidepressants Fig. 12 Funnel plot of all studies (Santarelli et al. 2003) cause the observed changes in cognitive function in parallel with changes in mood. This view is supported by McIntyre et al. (2014) who assessed the impact of Vortioxetine on cognition in MDD patients, and found that the beneficial effect of Vortioxetine was largely independent of its effect on improving depressive symptoms.
The current data indicates that antidepressants did not significantly affect expressive language, perceptual-motor skills, visuospatial skills or working memory for depressed persons. With the exception of working memory, these domains are less often found to be impaired in depression (Liotti and Mayberg 2001) , which could explain this finding. Working memory however has been reported to be impaired in depression by some researchers (Harvey et al. 2004; Rose and Ebmeier 2006 ), and it is surprising then that this aspect of cognition was not found to be positively affected by antidepressant use in depressed participants. There is considerable variability in the degree and type of cognitive dysfunction in depression, and one possible reason for this finding could be that working memory is less frequently, or to a lesser extent, impaired in depression. In line with this interpretation, some studies have indeed found no differences in working memory tasks between depressed and non-depressed persons (Barch et al. 2003; Walsh et al. 2007) , however further research into the effects of antidepressants and working memory would be worthwhile to clarify this finding.
Sub-group analyses of antidepressant class for each cognitive domain revealed that the SSRI's have the most consistent positive effect on cognition for depressed persons. Other newer generation antidepressants such as SMS's, SNRI's, SSRE's and NaSSA's tended to have modest or non-significant effects on cognitive functioning. The TCA's demonstrated non-significant effects that trended towards the negative in several cognitive domains. It is possible that the pharmacological profile of TCA's, which is known to produce some undesirable side effects including sedation and anticholinergic effects (Horst and Preskorn 1998) , may nullify the positive effects on cognition that are associated with the newer antidepressants.
When considering the results of the various classes of antidepressants, it should be noted that most of the studies included in the analysis investigated the effects of an SSRI. As such, confident conclusions regarding the cognitive effects of antidepressants other than SSRI's is limited by small samples and thus should be interpreted with caution. The current findings nevertheless align with previous work (Baune and Renger 2014; Boggio et al. 2005 ) that suggests that the SSRI's present the safest profile with regard to cognitive functioning.
Meta-regression did not reveal age to be significantly related to the overall effect of antidepressants on cognition. Similarly, when studies which included participants with a mean age of 60 years or less were compared with studies which included participants with a mean age over 60 years, the results were similar across age groups. In both groups, antidepressants were found to have a significant positive effect on cognition overall for depressed persons and in both the under and over 60 groups, antidepressants were found to have a non-significant effect on cognition overall in the non-depressed groups. While these results appear to suggest that antidepressants affect cognition in younger and older adults similarly, it is possible that age-related factors may impact upon the relationship between antidepressants and cognition at an individual level. It should be noted that the meta-regression technique applied to the current data is observational in nature and has been used to relate the SMD to an averaged characteristic (i.e. mean age per study) rather than individual level participant data, and as such may be impacted by ecological bias. That is, as noted by Petkova et al. (2013) , the relationship between the SMD and mean age may not be equal to the relationship between the outcome and the covariate in the individual studies.
It is also important to consider the potential differential effects of depression on the cognition of older adults as compared to younger adults. Research indicates that depression in older adults can be associated with more persistent cognitive deficits and even subsequent dementia (Butters et al. 2008) . Cognitive deficits have also been found to persist following treatment and remission of affective symptoms in older adults (Murphy and Alexopoulos 2004; Paradiso et al. 1997) . Although some researchers have questioned the safety of some antidepressant drugs with regard to cognition in older adults (Knegtering et al. 1994; Oxman 1996; Sommer et al. 2003) , much of the available evidence, including our current findings, suggests that apart from antidepressant agents with anticholinergic activity, antidepressant use in depressed older adults is associated with improved rather than impaired cognitive performance (Wang and Blazer 2015) .
When studies were grouped according to participant health status (i.e. healthy, degenerative neurological condition, stable neurological condition or psychiatric condition), no significant effects were found for the healthy or stable neurological condition group. Antidepressants were found to have a significant positive effect on cognition in the psychiatric group and the degenerative neurological condition group. Of note, a number of the studies included in the degenerative neurological condition group had a neurological condition (such as mild cognitive impairment) in addition to depression. It is likely then that the positive effect found in the degenerative neurological condition and psychiatric participant groups relates to the high proportion of participants with depression in these groups. This finding reinforces the suggestion that antidepressants are likely to be associated with improved cognition in depressed persons.
Pragmatically, the current findings endorse the usefulness of antidepressants in assisting people with depression, especially given that the cognitive symptoms of depression are associated with considerable disability and limited functional recovery (Jaeger et al. 2006; McCall and Dunn 2003; Naismith et al. 2007) . When considering the way in which antidepressant use may influence performance in a neuropsychological assessment setting, the results from the current meta-analysis suggest that in general, the use of antidepressant medication is unlikely to lead to erroneous diagnostic conclusions of cognitive impairment as a consequence of psychotherapeutic use of antidepressants. Of note however, while a positive effect of antidepressants for several cognitive domains was found for depressed persons, what is not revealed is whether this effect represents a return to pre-morbid levels, or 'normalisation' of cognitive function for these participants. Indeed, some research suggests that depression may be associated with persistent, trait like cognitive impairment (Sarapas et al. 2012 ), complicating the difficult task of parsing the cognitive effects of the depressed affective state, potential traitlike impairment and medication effects. As such, recognising the impact of depression on cognition remains important when undertaking cognitive assessment with depressed patients. Furthermore, the current findings are based on group data and when formulating opinion at the individual patient level the integration of multiple factors that modulate medicationinduced neurocognitive effects, such as chronicity of treatment, tolerance, age, interactions with other medications and other medical history for the individual patient is important (Stein and Strickland 1998) .
Limitations
There are several limitations of this meta-analysis that should be noted when considering the findings. Firstly, the results from a range of studies with differing methodologies were pooled. While it is acknowledged that the 'gold standard' of research is considered to be RCT's, there is as yet insufficient literature of this type to allow for detailed consideration of the effects of antidepressants on individual cognitive domains. Furthermore, a sensitivity analysis which investigated the different types of study designs included in the current analysis did not reveal significantly different results between study types. Also, although the current analysis was able to investigate several different domains of cognition, in the case of expressive language, perceptual motor skills and visuospatial-constructional skills, there was only one study that contributed data that focused on non-depressed participants. Further investigation of these domains would be worthwhile to generate sufficient data to enable calculation of a pooled effect.
Another limitation relates to the various cognitive tests that were used to assess each cognitive domain. This is a common problem when attempting to pool data on cognition due to the lack of a standard, widely administered testing protocol. Nevertheless, stringent inclusion criteria were employed which carefully considered the psychometric properties and standardised administration of tests used in potential studies. This was intended to increase the validity of the pooled effects for each cognitive domain. Furthermore, while the allocation of tests to cognitive domains were carefully considered and based on relevant sources, many of the included tests require a range of cognitive functions to be recruited in order to successfully undertake the task. Also, there remains a lack of consensus in the literature regarding the underlying constructs some neuropsychological tests measure, which results in differences in classification of some tests (Chaytor and Schmitter-Edgecombe 2003) . As such, it is plausible that the recategorisation of tests to alternative cognitive domains may impact the current findings.
Another issue regarding the cognitive tests included in the current analysis relates to the management of dependent effect sizes in cases where one study employed several tests to measure a single domain of cognitive functioning. As stated, an a priori hierarchy was developed which led to the inclusion of the results from neuropsychological tests most commonly in use. It is possible that the preference to include some tests over others in these few cases could have potentially influenced the observed results. An alternative way to deal with dependent effects in future research may be to conduct a three-level meta-analysis.
Moderate heterogeneity was identified when pooling the effects for immediate memory, processing speed and recent memory. This may have been caused by the pooling of studies that employed different methodologies, used different types of antidepressant drugs, and included studies with different durations of treatment, as shown in Table 2 . However, this heterogeneity was explored using moderation, regression and sensitivity analyses in an attempt to clarify the extent to which these variables may have impacted upon the current findings.
A further limitation relates to the analysis of age as a moderator. While the mean age of participants was provided by all of the included studies, information on the age range for participants was only available for 13 out of 32 included studies. Furthermore, given the wide age range of many studies, the mean age used in the moderator analyses may not capture the range of within study variability related to age. Given that when compared to younger adults, older adults may present with variations in depression type, additional cognitive impairment related to degenerative brain pathology and different reactions to antidepressants, further research that can more accurately differentiate the cognitive effects of antidepressants in younger and older adults is warranted.
Finally, the level of baseline cognitive impairment could potentially vary across the groups of participants included in the study, as well as within the depressed participant groups. It is possible that participants with greater cognitive impairment had the greatest scope for improvement in cognitive functioning, while those with high levels of cognitive functioning may have had less potential for improvement. Further research that can statistically control for change in depressive symptoms in conjunction with change in cognitive outcomes would therefore be of great value.
Conclusions
The current meta-analysis investigated the effects of antidepressants on various domains of cognitive functioning using a range of studies that included depressed and non-depressed participants. Results revealed that antidepressants have a modest, positive effect on divided attention, executive function, immediate memory, processing speed, recent memory and sustained attention for depressed participants. Antidepressants did not significantly affect cognitive function in non-depressed participants.
